NIFFENEGGER KATHI 4
4 · Edesa Biotech, Inc. · Filed Mar 7, 2022
Insider Transaction Report
Form 4
NIFFENEGGER KATHI
Chief Financial Officer
Transactions
- Award
Stock Option (right to buy)
2022-02-28+43,500→ 43,500 totalExercise: $3.71Exp: 2032-02-28→ Common Shares (43,500 underlying)
Footnotes (1)
- [F1]This option vests monthly in equal proportions over 36 months beginning on the Grant Date.